{"id":251052,"date":"2022-03-15T00:00:00","date_gmt":"2022-03-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/exinhe0001-2022-biopharma-hemolytic-disease-of-the-fetus-and-newborn\/"},"modified":"2026-04-22T17:21:55","modified_gmt":"2026-04-22T17:21:55","slug":"exinhe0001-2022-biopharma-hemolytic-disease-of-the-fetus-and-newborn-executive-insights-hemolytic-disease-of-the-fetus-and","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinhe0001-2022-biopharma-hemolytic-disease-of-the-fetus-and-newborn-executive-insights-hemolytic-disease-of-the-fetus-and\/","title":{"rendered":"Hemolytic Disease of the Fetus and Newborn – Executive Insights – Hemolytic Disease of the Fetus and Newborn | Executive Insights | US\/EU5"},"content":{"rendered":"

Hemolytic disease of the fetus and newborn (HDFN<\/abbr>), also known as alloimmune HDFN<\/abbr> or erythroblastosis fetalis, is a rare red blood cell disorder in which maternal antibodies attack the red blood cells of fetuses and newborn babies. Improving the hematocrit levels in fetuses and reducing the total serum bilirubin levels in newborns are the key goals of treatment. Anti-D prophylaxis is approved to prevent HDFN<\/abbr>, but there is no approved curative therapy. Patients are managed with phototherapy, transfusions, and off-label drugs such as intravenous immunoglobulins. The only treatment in the prenatal stage is an invasive and risky intrauterine transfusion. The pipeline for HDFN<\/abbr> is sparse; only a few companies are developing therapies for the indication. Janssen\u2019s nipocalimab, a promising FcRn<\/abbr> antagonist, is expected to launch in the United States and Europe in the next few years. In the meantime, treatment of HDFN<\/abbr> is associated with substantial unmet need, including the lack of a cure. This therapy market represents significant commercial opportunity.<\/p>\n

QUESTIONS ANSWERED<\/strong><\/p>\n